Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 2/20 | 0.56 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.56 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | CD69 | Q07108 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.43 |
| ▸ | MAG | P20916 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15081898 | 1.00 | LGALS3 (0.56) | LGALS3LGALS8LGALS4ALDH1A1THRB | |
| SCHEMBL15081897 | 0.93 | LGALS3 (0.62) | LGALS3LGALS8LGALS4ALDH1A1THRB | |
| SCHEMBL21064186 | 0.93 | LGALS3 (0.62) | LGALS3LGALS8LGALS4ALDH1A1THRB | |
| SCHEMBL17573071 | 0.93 | LGALS3 (0.62) | LGALS3LGALS8LGALS4ALDH1A1THRB | |
| SCHEMBL20122238 | 0.93 | LGALS3 (0.62) | LGALS3LGALS8LGALS4ALDH1A1THRB | |
| SCHEMBL21064180 | 0.90 | LGALS3 (0.52) | LGALS3LGALS8LGALS4ALDH1A1THRB | |
| SCHEMBL17586052 | 0.90 | LGALS3 (0.52) | LGALS3LGALS8LGALS4ALDH1A1THRB | |
| SCHEMBL21695250 | 0.90 | MAPK1 (0.50) | LGALS3LGALS8LGALS4ALDH1A1THRB | |
| SCHEMBL22351815 | 0.89 | LGALS3 (0.62) | LGALS3LGALS8LGALS4ALDH1A1THRB | |
| SCHEMBL18300844 | 0.87 | LGALS3 (0.60) | LGALS3LGALS8LGALS4ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119437-A1 | SYNTHESIS OF OLIGOSACCHARIDES | GLYCOM AS (DK) | 2022-04-21 | — | — | US | disclosed |
| US-11214588-B2 | Synthesis of oligosaccharides | GLYCOM A/S (DK) | 2022-01-04 | — | — | US | disclosed |
| US-11142541-B2 | Purification of oligosaccharides | GLYCOM A/S (DK) | 2021-10-12 | — | — | US | disclosed |
| US-20200215486-A1 | SYNTHESIS OF OLIGOSACCHARIDES | GLYCOM A/S (DK) | 2020-07-09 | — | — | US | disclosed |
| US-20200148793-A1 | PURIFICATION OF OLIGOSACCHARIDES | GLYCOM A/S (DK) | 2020-05-14 | — | — | US | disclosed |
| US-20200123184-A1 | PURIFICATION OF OLIGOSACCHARIDES | GLYCOM A/S (DK) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123184-A1 | PURIFICATION OF OLIGOSACCHARIDES | FUT5, FUT6, LCT | LGALS3 110/4885LGALS8 101/4885LGALS4 87/4885 |
| US-11142541-B2 | Purification of oligosaccharides | OSTC, FUT5, FUT6 | LGALS3 74/4885LGALS8 37/4885LGALS4 31/4885 |
| US-11214588-B2 | Synthesis of oligosaccharides | MGAM, LCT, LPO | LGALS3 969/4885LGALS8 348/4885LGALS4 577/4885 |
| US-20220119437-A1 | SYNTHESIS OF OLIGOSACCHARIDES | MGAM, LCT, LPO | LGALS3 969/4885LGALS8 348/4885LGALS4 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.